
    
      PRV-3279-1b is a Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to
      Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of
      PRV-3279 in Healthy Subjects.

      Eligible subjects include healthy male or female adults, 18 to 50 years of age. Each subject
      will receive the assigned treatment over 29 days followed by a 56-day follow-up period.
    
  